The accumulation of particular protein deposits connected to molecular mechanisms is one of the many brain abnormalities associated with Alzheimer's disease (AD), a complex neurodegenerative illness. There are currently no effective disease-modifying treatments for AD.
Objective
This study attempts to identify potential AD therapeutics through a biological network-based drug repurposing strategy, focusing on drugs targeting important proteins and biological pathways involved in AD pathology.
Methods
A comprehensive biological network of AD-associated molecules and their transcription regulatory interactions is constructed. This computational approach integrates data from genome-wide association studies, multiple AD-related magnetic resonance imaging (MRI) derived phenotypes, biomolecular interactions, and gene expression profiles.
Results
The constructed AD sub-regulatory network reveals significant correlations between transcription factors showing changed gene expression in AD patients relative to controls. This strategy prioritizes drug candidates based on their mechanisms of action, reducing the risk of clinical trial failures and enhancing patient outcomes related to AD. A total of 43 drug candidates have been identified, including 28 FDA-approved drugs, 15 experimental and investigational drugs that may alter biological processes pertaining to important facets of AD pathology. Baricitinib and Gabapentin emerge as promising candidates for targeting AD-related biological processes in the cerebral cortex and hippocampus regions.
Conclusions
By combining biological network analysis and MRI-driven transcriptome-wide association study, this systematic drug repurposing strategy demonstrates promise for identifying novel therapeutic options for AD and offers potential implications for addressing other complex neurological disorders.
Lopez-BuenoRYangLStamatakisE, et al.Moderate and vigorous leisure time physical activity in older adults and Alzheimer's disease-related mortality in the USA: a dose-response, population-based study. Lancet Healthy Longev2023; 4: e703–e710.
3.
KodamullilATZekriFSoodM, et al.Trial watch: tracing investment in drug development for Alzheimer disease. Nat Rev Drug Discov2017; 16: 819.
4.
SinhaPBarocasJA. Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price. Alzheimers Dement (N Y)2022; 8: e12256.
5.
BallardCAarslandDCummingsJ, et al.Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol2020; 16: 661–673.
6.
RodriguezSHugCTodorovP, et al.Machine learning identifies candidates for drug repurposing in Alzheimer's disease. Nat Commun2021; 12: 1033.
7.
BoylePAYuLLeurgansSE, et al.Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol2019; 85: 114–124.
8.
WightmanDPJansenIESavageJE, et al.A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet2021; 53: 1276–1282.
9.
FabbriCPainOHagenaarsSP, et al.Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology2021; 46: 1821–1829.
10.
GockleyJMontgomeryKSPoehlmanWL, et al.Multi-tissue neocortical transcriptome-wide association study implicates 8 genes across 6 genomic loci in Alzheimer's disease. Genome Med2021; 13: 76.
11.
UddinMSKabirMTAl MamunA, et al.APOE And Alzheimer's disease: evidence mounts that targeting APOE4 may combat Alzheimer's pathogenesis. Mol Neurobiol2019; 56: 2450–2465.
12.
FrisoniGBFoxNCJackCRJr, et al.The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol2010; 6: 67–77.
13.
SchillingKGArcherDYehFC, et al.Aging and white matter microstructure and macrostructure: a longitudinal multi-site diffusion MRI study of 1218 participants. Brain Struct Funct2022; 227: 2111–2125.
14.
SudlowCGallacherJAllenN, et al.UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med2015; 12: e1001779.
15.
MillerKLAlfaro-AlmagroFBangerterNK, et al.Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat Neurosci2016; 19: 1523–1536.
16.
Alfaro-AlmagroFJenkinsonMBangerterNK, et al.Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage2018; 166: 400–424.
17.
ElliottLTSharpKAlfaro-AlmagroF, et al.Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature2018; 562: 210–216.
18.
ChewHSolomonVAFontehAN. Involvement of lipids in Alzheimer's disease pathology and potential therapies. Front Physiol2020; 11: 598.
19.
SiavelisJCBourdakouMMAthanasiadisEI, et al.Bioinformatics methods in drug repurposing for Alzheimer's disease. Brief Bioinform2016; 17: 322–335.
20.
UddinMSAl MamunAKabirMT, et al.Multi-target drug candidates for multifactorial Alzheimer's disease: aChE and NMDAR as molecular targets. Mol Neurobiol2021; 58: 281–303.
21.
SwarupVHinzFIRexachJE, et al.Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat Med2019; 25: 152–164.
22.
HopkinsAL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol2008; 4: 682–690.
23.
WangXWangZYZhengJH, et al.TCM Network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med2021; 19: 1–11.
24.
TankRWardJFlegalKE, et al.Association between polygenic risk for Alzheimer's disease, brain structure and cognitive abilities in UK biobank. Neuropsychopharmacology2022; 47: 564–569.
HaoSWangRZhangY, et al.Prediction of Alzheimer's disease-associated genes by integration of GWAS summary data and expression data. Front Genet2018; 9: 653.
27.
GusevAKoAShiH, et al.Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet2016; 48: 245–252.
28.
AdamsDMReayWRCairnsMJ. Multiomic prioritisation of risk genes for anorexia nervosa. Psychol Med2023; 53: 6754–6762.
29.
MencheJSharmaAKitsakM, et al.Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science2015; 347: 1257601.
30.
WishartDSFeunangYDGuoAC, et al.Drugbank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res2018; 46: D1074–D1082.
31.
WangMRoussosPMcKenzieA, et al.Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Med2016; 8: 104.
32.
GreenwoodAKMontgomeryKSKauerN, et al.The AD knowledge portal: a repository for multi-omic data on Alzheimer's disease and aging. Curr Protoc Hum Genet2020; 108: e105.
33.
KeenanABTorreDLachmannA, et al.ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res2019; 47: W212–W224.
34.
ChenEYTanCMKouY, et al.Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics2013; 14: 128.
35.
SwahnHOlmerMLotzMK. RNA-binding proteins that are highly expressed and enriched in healthy cartilage but suppressed in osteoarthritis. Front Cell Dev Biol2023; 11: 1208315.
36.
Rivero-GarciaICastresana-AguirreMGuglielmoL, et al.Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19. Sci Rep2021; 11: 20687.
37.
AmbreeORichterHSachserN, et al.Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging2009; 30: 1192–1204.
38.
SoedaYYoshikawaMAlmeidaOF, et al.Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat Commun2015; 6: 10216.
39.
RosenbergPBLanctotKLDryeLT, et al.Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry2013; 74: 810–816.
40.
SupasitthumrongTBolea-AlamanacBMAsmerS, et al.Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. Br J Clin Pharmacol2019; 85: 690–703.
41.
RautSBBolegaveSSMarathePA. Effect of flumazenil on memory retrieval determined by trial-to-criteria inhibitory avoidance method in mice. J Pharmacol Pharmacother2016; 7: 24–26.
42.
GomaaAAFarghalyHSMAhmedAM, et al.Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats. Int Immunopharmacol2023; 117: 109927.
43.
XuCLiuGJiH, et al.Elevated methylation of OPRM1 and OPRL1 genes in Alzheimer's disease. Mol Med Rep2018; 18: 4297–4302.
44.
WangYChenGShaoW. Identification of ferroptosis-related genes in Alzheimer's disease based on bioinformatic analysis. Front Neurosci2022; 16: 823741.
45.
KrohnMLangeCHofrichterJ, et al.Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest2011; 121: 3924–3931.
46.
OzdemirZAlagozMABahceciogluOF, et al.Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimer's and Parkinson's disease. Curr Med Chem2021; 28: 6045–6065.
47.
ChenJF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol2014; 119: 257–307.
48.
GreeneJALoscalzoJ. Putting the patient back together – social medicine, network medicine, and the limits of reductionism. N Engl J Med2017; 377: 2493–2499.
49.
ChengFDesaiRJHandyDE, et al.Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun2018; 9: 2691.
50.
PengYYuanMXinJ, et al.Screening novel drug candidates for Alzheimer's disease by an integrated network and transcriptome analysis. Bioinformatics2020; 36: 4626–4632.
51.
LiuAManuelAMDaiY, et al.Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data. Hum Mol Genet2022; 31: 3341–3354.
52.
ZhouZChenFZhongS, et al.Molecular identification of protein kinase C beta in Alzheimer's disease. Aging (Albany NY)2020; 12: 21798–21808.
53.
FangJZhangPWangQ, et al.Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease. Alzheimers Res Ther2022; 14: 7.
54.
UddinMSTewariDSharmaG, et al.Molecular mechanisms of ER stress and UPR in the pathogenesis of Alzheimer's disease. Mol Neurobiol2020; 57: 2902–2919.
55.
SharmaVKSinghTGGargN, et al.Dysbiosis and Alzheimer's disease: a role for chronic stress?Biomolecules2021; 11: 678.
56.
CummingsJLeeGZhongK, et al.Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y)2021; 7: e12179.
57.
RahmanMHAkterRBhattacharyaT, et al.Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer's disease. Front Pharmacol2020; 11: 619024.
58.
AgarwalKKatareDPJakhmola-ManiR. Foresee novel targets for Alzheimer's disease by investigating repurposed drugs. CNS Neurol Disord Drug Targets2022; 22: 1209–1231.
59.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
60.
CuddyLKAliaAOSalvoMA, et al.Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice. Mol Neurodegener2022; 17: 54.
61.
HindamMOAhmedLAEl SayedNS, et al.Repositioning of baricitinib for management of memory impairment in ovariectomized/D-galactose treated rats: a potential role of JAK2/STAT3-PI3K/AKT/mTOR signaling pathway. Life Sci2024; 351: 122838.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
